Key clinical trials of Ivosidenib
| Drug(s) | Indication | Phase | Status | Location(s) | Identifier | Sponsor |
|---|---|---|---|---|---|---|
| Ivosidenib, placebo | Untreated AML | 3 | Recruiting | Multnational | NCT03173248; AGILE; AG120-C-009 | Agios Pharmaceuticals, Inc |
| Ivosidenib, placebo | Advanced cholangiocarcinoma | 3 | Recruiting | Multinational | NCT02989857; A G120-C-005 | Agios Pharmaceuticals, Inc |
| Ivosidenib | R/R AML | EA | Approved for marketing | NA | NCT03245424; AG120-C-010 | Agios Pharmaceuticals, Inc |
| Ivosidenib | Myelodysplastic syndrome | 2 | Planned | NA | NCT03503409; IDIOME-STUDY | Groupe Francophone des Myelodysplasies |
| Ivosidenib, other targeted agents | Untreated AML | 1b/2 | Recruiting | USA | NCT03013998; BAML-16-001 | Beat AML, LLC |
| Ivosidenib/enasidenib (with azacitidine) | Newly diagnosed AML | 1b/2 | Recruiting | Multinational | NCT02677922; AG-221-AML-005 | Celgene |
| Ivosidenib, venetoclax | Haematologic malignancies | 1b/2 | Recruiting | NA | NCT03471260; 2017-0490 | MD Anderson Cancer Center |
| Ivosidenib | Myeloid neoplasms | 1 | Planned | USA | NCT03564821; 18-123 | Massachusetts General Hospital |
| Ivosidenib, enasidenib (with chemotherapy) | Newly diagnosed AML | 1 | Recruiting | USA, Germany, Netherlands | NCT02632708; AG120-221-C-001 | Agios Pharmaceuticals, Inc |
| Ivosidenib | Advanced haematological malignancies (including R/R AML) | 1 | Ongoing | USA, France | NCT02074839; AG120-C-001 | Agios Pharmaceuticals, Inc |
| Ivosidenib | Advanced solid tumors | 1 | Ongoing | USA, France | NCT02073994; AG120-C-002 | Agios Pharmaceuticals, Inc |
| Ivosidenib, vorasidenib | Recurrent, non-enhancing, low-grade glioma | 1 | Recruiting | USA | NCT03343197; AG120-881-C-001 | Agios Pharmaceuticals, Inc |
AML acute myeloid leukaemia, EA expanded access, NA not available, R/R relapsed or refractory